Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain by Upadhyay, Urvashi M. et al.
Intracranial microcapsule chemotherapy delivery for
the localized treatment of rodent metastatic breast
adenocarcinoma in the brain
Urvashi M. Upadhyaya,1, Betty Tylerb, Yoda Pattac, Robert Wicksb, Kevin Spencerc, Alexander Scottc, Byron Masid,
Lee Hwangb, Rachel Grossmanb, Michael Cimac,e, Henry Bremb,f,g, and Robert Langerd,e,1
aDepartment of Neurosurgery, Brigham and Women’s Hospital, Boston, MA 02115; bDepartment of Neurosurgery, Johns Hopkins University Hospital,
Baltimore, MD 21231; Departments of cMaterials Science and Engineering and dChemical Engineering and eKoch Institute for Integrative Cancer
Research, Massachusetts Institute of Technology, Cambridge, MA 02139; and Departments of fOncology and gBiomedical Engineering, Johns Hopkins
University Hospital, Baltimore, MD 21205
Contributed by Robert Langer, July 17, 2013 (sent for review August 14, 2012)
Metastases represent the most common brain tumors in adults.
Surgical resection alone results in 45% recurrence and is usually
accompanied by radiation and chemotherapy. Adequate chemo-
therapy delivery to the CNS is hindered by the blood–brain barrier.
Efforts at delivering chemotherapy locally to gliomas have shown
modest increases in survival, likely limited by the infiltrative nature
of the tumor. Temozolomide (TMZ) is first-line treatment for glio-
mas and recurrent brain metastases. Doxorubicin (DOX) is used in
treating many types of breast cancer, although its use is limited by
severe cardiac toxicity. Intracranially implanted DOX and TMZ
microcapsules are compared with systemic administration of the
same treatments in a rodent model of breast adenocarcinoma brain
metastases. Outcomes were animal survival, quantified drug expo-
sure, and distribution of cleaved caspase 3. Intracranial delivery of
TMZ and systemic DOX administration prolong survival more than
intracranial DOX or systemic TMZ. Intracranial TMZ generates the
more robust induction of apoptotic pathways. We postulate that
these differences may be explained by distribution profiles of each
drug when administered intracranially: TMZ displays a broader dis-
tribution profile than DOX. These microcapsule devices provide
a safe, reliable vehicle for intracranial chemotherapy delivery and
have the capacity to be efficacious and superior to systemic delivery
of chemotherapy. Future work should include strategies to improve
the distribution profile. These findings also have broader implica-
tions in localized drug delivery to all tissue, because the efficacy of
a drug will always be limited by its ability to diffuse into surround-
ing tissue past its delivery source.
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The rationale behind localized drug delivery is that high con-centrations of drug may be reached in target tissue while
minimizing systemic exposure to the large quantities of drug that
might otherwise be necessary to achieve the desired biologic effect.
Localized drug delivery has been used, such as in drug-eluting
stents for coronary artery disease, metered dose inhalers for the
treatment of asthma, and intracranial chemotherapy wafers for
brain tumors. This premise is particularly applicable to conditions
affecting tissue that is sequestered from systemic circulation, such
as conditions affecting the CNS.
Adequate and efficacious drug delivery to the CNS has proved
challenging. Systemic delivery methods are hindered by low
permeability at the blood–brain barrier (BBB) to nonlipophilic
drugs, which requires high systemic doses to be administered,
thereby increasing systemic toxicity (1, 2). One method of cir-
cumventing the BBB is to place polymers that can release drug in
a time-controlled manner at the site of tumor resection (3–6).
Localized drug delivery devices provide high drug concentrations
to the tumor site while preventing drug degradation and clearance
until its release (7, 8). The efficacy of current intracranial drug
delivery, such as Carmustine wafers, has promise, with a doubling
of median survival from 9 to 20 mo in the case of Carmustine
wafers (6, 9, 10). Phase III trial data indicated a 2-to 3-mo survival
advantage in Carmustine wafers-treated patients (11), and Car-
mustine wafers continue to have a role combined with radiation
and oral temozolomide (TMZ). However, nearly all patients still
succumb to tumor progression.
The clinical focus of CNS drug delivery has been high-grade
glioma (12). The modest increases in survival seen with such
strategies have been attributed, in part, to the limited efficacy of
the chemotherapies used and the disease target itself, because
these tumors are among the most infiltrative and aggressive tumors
studied (6, 8). It has also been postulated that the chemotherapy
that has been used (Carmustine) does not diffuse well through
brain tissue to produce tissue effects away from the implantation
site. Such strategies have not been widely tested in more focal,
noninfiltrative lesions of the brain, such as brain metastases. Sev-
eral experiments have been conducted with polymer-based vehi-
cles, which locally delivery chemotherapy, that suggest their
efficacy in brain metastases (13). The microcapsules described here
were studied in a rodent glioma model and showed tunable release
kinetics and efficacy (12). These vehicles have, however, not been
tested in brain metastases.
Metastases to the brain are the most commonly encountered
tumors in the brain (14–17). It is estimated that 100,000–200,000
new cases are identified in the United States each year. Fur-
thermore, 20% of patients with disseminated cancer have evi-
dence of CNS involvement at autopsy (14). Certain tumors have
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a predilection to metastasize to the brain with nonsmall cell lung
cancer, breast carcinoma, small cell lung carcinoma, malignant
melanoma, renal cell carcinoma, gastrointestinal carcinoma, uter-
ine carcinoma, and unknown primary carcinoma in decreasing
frequency (14, 15). Cell surface markers seem to predict metastatic
potential; for example, human epidermal growth factor receptor
2-positive breast carcinoma is more likely to present with CNS
lesions (16). Metastases are focal in nature, with no true invasion
of brain tissue in contrast to high-grade gliomas.
The treatment of brain metastases is often multimodal, with
surgery, whole-brain radiotherapy (WBRT), stereotactic radio-
surgery, and chemotherapy all playing a role (18, 19). The selec-
tion of specific modalities of treatment is dependent on patient-
specific factors, such as number, size, and location of metastases,
patient’s overall health and prognosis, and degree of symptoms
attributable to these metastases. Surgery remains a standard treat-
ment for metastatic lesions, particularly those that are symptomatic
for patients with good functional status and well-controlled extra-
cranial disease (19). Metastases tend to be noninfiltrative histo-
logically, suggesting that surgical treatment should reduce or
eliminate tumor burden and be beneficial. Multiple retrospective
analyses have shown survival benefit from resection of single
brain metastases, particularly combined with WBRT (19–22).
More recent data from 2005 suggest that patients with two or
three metastases also show increases in overall survival when the
dominant symptomatic lesion is surgically resected (23). The
most promising trial of combination chemotherapy showed re-
sponse rates of 40–59% in breast cancer metastases to the brain
(24), although more recent studies show a wide range of response
from 10% to 45%, with variability based on the primary tumor
(19). Systemic chemotherapy delivery has played a limited role in
the treatment of brain metastases, in part because of the poor
penetration through the BBB (19). More recent studies suggest
that chemotherapeutic agents that have better penetration of the
BBB, such as TMZ, may have a role in newly diagnosed metas-
tases, not just as salvage therapy (25, 26). The agents that have
shown promise include cyclophosphamide, 5-fluorouracil, metho-
trextate and vincristine combined, and TMZ, although the use of
TMZ has been restricted to recurrent breast metastases (19, 27,
28). The use of TMZ in recurrent breast cancer brain metastases
has shown modest increases in survival, although this patient
population represents a selection of the most aggressive and re-
fractory cancers that have withstood surgery, WBRT, and multiple
other systemic chemotherapies.
Doxorubicin (DOX) has been used to treat early-stage, node-
positive breast cancer, particularly HER2-positive tumors, al-
though it is more commonly used for treatment of non-Hodgkins
lymphoma and certain leukemias (29). Its clinical use in breast
metastases to the brain has largely been limited by the resistance
of the tumor to the chemotherapy as well as its poor penetration
of the BBB and its dose-related adverse effects. The risk of de-
veloping potentially lethal cardiotoxicity increased significantly
when doses of DOX reach 500 mg/m2 (30).
Microcapsules loaded with DOX or TMZ were administered
intracranially in an experimental model of metastases to the brain
in the following set of experiments. The CRL1666 cell line has
been used in a metastatic spine model. This body of work rep-
resents the first time that it has been successfully used in a brain
metastasis model to the best of our knowledge (31). Their efficacy
was compared with systemic administration of DOX and TMZ.
Tissue harvested from these animals was then processed for evi-
dence of induction of apoptosis, and the distribution of drug re-
leased from the devices was also examined to test the relationship
between drug distribution and biologic activity and efficacy.
Results
TMZ Liquid Crystal Polymer Devices. Liquid crystal polymer (LCP)
is nonbiodegradable but biocompatible and inert, and its liquid
crystal structure along with polymer chain rigidity do not allow
drug partitioning through its membrane, which has been an issue
with other polymer compounds used (such as polylactic acid).
Fick’s Law of Diffusion was used to estimate the rate of drug
delivery from microcapsule devices for the device prototype.
Release kinetics were controlled by the diameter of device ori-
fices, the number of orifices, and the solubility of the drug. The
inner volume of the reservoir measured 1.5 mL, which allowed for
higher drug loading per device volume compared with previous
drug delivery devices (10, 32). One important innovation in this
work was the use of the injection molding process for high-pre-
cision device production, which gave reliable and consistent
results, including very small tolerances in volume. These devices
can be engineered to achieve desired release kinetics. These
devices are not biodegradable and were intact on retrieval from
brain tissue at the time of animal euthanasia without evidence of
biofouling. Multiple-orifice microcapsules were fabricated to in-
crease the release rate of TMZ. These devices were manufactured
with a total of five orifices for drug release: one 889-μm-diameter
orifice in the cap and four 403-μm-diameter orifices around the
circumference of the microcapsule reservoir. The theoretical re-
lease rate of TMZ from a single 889-μm-diameter orifice micro-
capsule was calculated by calculation of the flux (J) and the area
(A) over which drug release occurs. The release rate of TMZ from
these devices was found to be 2.5 × 10−5 mg/s or 2.16 mg/d (Fig. 1).
In Vitro TMZ Drug Release Kinetics. The in vitro release of TMZ
from the LCP microcapsules into HPLC-grade water was assayed
by HPLC. Control devices with sealed orifices were fabricated to
test the hermeticity of the UV-curable epoxy and polymer housing.
A theoretical release curve based on Fick’s Law was constructed
for comparison with experimental drug release data. The calcu-
lated mass flow rate was 90 mg/h. The experiment was completed
in triplicate. Results were reported as average values with SDs.
The experimental release curves were in agreement with the the-
oretical release curve. The experimental TMZ release rate during
the first 100 h of release was 88 mg/h ± 6.75 μg. At this time, 67%
of the total 12-mg payload was released. The release rate de-
creased after 100 h, with 71% after 190 h. The devices fabri-
cated for drug leak tests showed that the epoxy sealed the
devices, preventing leakage. No drug partitioning through the
polymer housing was detected, suggesting that LCP is capable of
storing TMZ throughout the length of therapy.
In Vitro DOX Drug Release Kinetics. The in vitro release of DOX
from LCP microcapsules was assayed using spectroscopy. A the-
oretical release curve was again constructed for comparison with
experimental release data. The calculated mass flow rate for sin-
gle-orifice devices was 1.21 mg/d. The calculated rate for multiple-
hole devices was 2.16 mg/d (Fig. 2). The experiment was com-
pleted in triplicate. Results were reported as average values with
SDs. At 300 h, nearly 70% of the 1-mg payload was released from
single-orifice devices. Multiple-hole devices released 70% of the
payload from multiple-hole devices over a shorter time period
(Fig. 2). The experimental and theoretical release curves were
in agreement.
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Fig. 1. TMZ LCP device in vitro release.
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In Vivo Efficacy Experiments.
Efficacy of locally delivered DOX and TMZ. The primary efficacy out-
come was animal survival (Fig. 3). The median survival of un-
treated control animals was 11 d, with mean of 10 d. Animals with
unfilled (blank) LCP-implanted devices had mean and median
survival of 12 d. Animals with DOX-loaded LCP devices (payload =
5 mg) had mean and median survival of 14 d. Rats from the
systemic DOX and intracranial TMZ microcapsule groups
exhibited longer survival rates. TMZ LCP device-treated animals
had median and mean survival of 19 and 18 d, respectively, with
all dying at 21 d. DOX-treated animals had mean and median
survival of 19 d, with all animals dying by 25 d. Statistical anal-
yses of the survival data were performed, and significant differ-
ences were observed between the control/DOX (P < 0.05),
control/TMZ (P < 0.05), blank/DOX (P < 0.05), and blank/TMZ
(P < 0.05) groups. There was no statistical significance shown
between the control and DOX microcapsule groups.
The second in vivo experiment tested the efficacy of DOX
microcapsules loaded with lower payload (3.5 and 5 mg) against
other groups. Animal survival was the primary outcome measure
(Fig. 4). Untreated control animals experienced a median sur-
vival of 13 d. Those animals treated with DOX LCP micro-
capsules (payload = 5 mg) had median survival of 13 d and mean
survival of 15 d. Animals treated with DOX LCP devices (pay-
load = 3.5 mg) had median and mean survival of 12 and 13 d,
respectively. DOX animals had median survival of 18 d, with
mean survival of 13 d. Animals treated with oral TMZ had mean
and median survival of 19 d, with all animals dying by 21 d.
Animals with TMZ microcapsules had median and mean survival
of 21 and 25 d, respectively, with all dying by 56 d. Significant
differences were observed between control/oral TMZ (P < 0.05),
control/TMZ LCP (P = 0.01), DOX LCP (5 mg)/TMZ LCP
(P = 0.02), DOX LCP (3.5 mg)/TMZ LCP (P = 0.02), and DOX/
TMZ LCP (P = 0.01). Increased survival in TMZ LCP micro-
capsules was not statistically significant compared with oral TMZ
administration (P = 0.09).
Cleaved caspase 3 expression on immunohistochemistry. Brain tissue
harvested from the in vivo efficacy studies was formalin-fixed and
paraffin-embedded for immunohistochemistry. Coronal sections
were obtained from each treatment group. Cells expressing the
cleaved caspase 3 protein were counted per high-power field
(hpf) in all sections and compared between treatment groups
(Fig. 5). Untreated control animals had an average of 12 cells/
hpf. DOX animal tissue had, on average, 10 cells/hpf. DOX LCP
(5 mg) animal tissue had 81 cells/hpf. Blank LCP tissue had an
average of 2 cells/hpf. TMZ LCP animal tissue had 103 cells/hpf.
Using the unpaired t test, significant differences were observed
between control/DOX microcapsule (P < 0.05), control/TMZ
microcapsule (P < 0.05), control/oral TMZ (P = 0.001), DOX/
DOX microcapsule (P < 0.05), and oral TMZ/TMZ microcap-
sule (P = 0.003).
Drug distribution after release from microcapsules. Healthy rodent
brain tissues exposed to microcapsules filled with DOX or TMZ
were examined for the spatial distribution of drug released over
time (Fig. 6). Microcapsules loaded with DOX achieved narrow
distribution, with a large peak seen at the sight of implantation
and a steep drop out of drug level within 0.25 cm. Rodent tissue
exposed systemically to DOX showed low but uniform levels
of DOX. Microcapsules loaded with TMZ achieved broader
distribution, with more uniform levels of drug seen within 0.5 cm,
and a dropout was seen around 0.7 cm. Systemic TMZ achieved
a similar distribution profile but with lower exposure levels than
TMZ delivered through microcapsule.
Discussion
A growing trend in pharmacology is designing targeted therapies
that minimize indiscriminate delivery and maximize delivery to
the desired end organ. Multiple strategies have been used, in-
cluding nanoparticle-driven delivery, liposomal formulation, and
local delivery. Each strategy aims to minimize systemic toxicity.
In these experiments, intracranial drug delivery was explored in
metastatic breast tumors to the brain. The findings suggest that
local chemotherapy delivery may be more efficacious than its
systemic delivery, and this efficacy may hinge on drug diffusion.
The broader implication for delivery outside the CNS is that
successful local delivery depends on the efficacy and distribution
of the drug. For those drugs that show strong biologic efficacy
but with narrow distribution, strategies to improve distribution,
such as chemical modification, should be deployed to improve
their tissue penetration.
In Vitro Drug Release. The rates of microcapsule devices exhibited
close agreement with theoretical rates for the first 100 h of re-
lease. The release from single- and multiple-hole microcapsules
plateaus after this time as chemical driving force decreases for
diffusion. This plateau results in slower drug diffusion than
theoretically predicted. The stability of TMZ also has a profound
impact on the in vitro release kinetics. TMZ is a prodrug that
quickly degrades into the bioactive MTIC (3-methyl-(triazen-1-
yl)imidazole-4-carboxamide) molecule under basic conditions
and in high-ionic strength solvents (32). This instability does not
seem to be the case for DOX, because it is not a prodrug. In vitro
release into water differs from in vivo conditions. The half-life of
TMZ in water is considerably greater than its half-life in PBS, in
FBS, and in vivo (32). This difference accounts for the close
agreement with theory that is seen during the first 100 h of the
TMZ water release profiles. Degradation of TMZ because of its
instability in solution may account for the observed plateau and
may explain why 100% drug is not released experimentally.
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The microcapsule was designed for delivery of a large payload
from a device small enough for rodent intracranial implantation.
The tight dimensional tolerances between the rodent skull and the
microcapsule device along with the introduction of a growing tu-
mor could cause brain damage because of increased intracranial
pressure (mass effect). This mass effect is pronounced in metas-
tases patients and the primary indication for tumor resection sur-
gery. The consequence of mass effect is shown in the short survival
of blank microcapsule groups.
The microcapsule represents an improvement over prior in-
tracranial delivery. As a reservoir-based vehicle, it maximizes
payload delivered per unit volume compared with other local de-
livery strategies, such as polymer-composite wafers. Microcapsules
are capable of delivering solid or liquid drug formulations, an
ability that polymer-composite wafers do not currently possess.
Such devices may house multiple classes of therapeutics: not just
chemotherapy but macromolecules or tumor-directed viral par-
ticles. Release kinetics may be reliably tuned without the need for
polymer degradation to occur for drug release, because the mi-
crocapsule is made from LCP, which does not permit drug parti-
tioning. These properties allow for highly versatile and tun-
able drug delivery with the possibility of delivering a wide range
of therapeutic compounds to brain tumors as well as other
human diseases.
In Vivo Experiments. The in vivo efficacy of localized TMZ and
DOX therapy was investigated in a rodent breast metastasis
model. TMZ microcapsules most effectively prolonged animal
survival rates, and these results reached statistical significance in
both experiments. Systemic DOX also showed prolonged survival
compared with controls. Interestingly, DOX microcapsules did
not show prolonged survival, regardless of payload chosen, sug-
gesting that intracranial delivery is not always the most efficacious
delivery route. Locally delivered TMZ is equivalent or superior to
systemic TMZ. However, locally delivered DOX does not per-
form as well as systemic DOX. Systemic DOX is delivered in a
liposomal formulation, which aides in its ability to evade the
recticuloendothelial system, circulating longer. The differ-
ences in survival may be explained by distribution profiles seen
in these experiments. Intracranial TMZ and systemic DOX do
achieve more uniform distributions compared with intracranial
DOX delivery, which seems to be quite narrow. Oral TMZ was
administered 5 d after tumor implantation to mimic the peak
release of TMZ from our device.
Intracranial DOX had narrow distribution, with levels drop-
ping significantly at 2.5 mm, compared with the broader profile
of intracranial TMZ, with drop off first seen at 5–7 mm. Strasser
et al. (33) found that drug delivered from a biodegradable
polymer implant was seen to diffuse only 1–2 mm from the site of
implantation (33, 34). The reasons for the differences observed
could be twofold: the polymer composite delivery vehicle may
impact drug distribution itself, or the chemical properties of the
agent delivered [BCNU (bis-chloroethylnitrosourea), DOX, or
TMZ] are the larger determinant of the ability to diffuse in tissue.
Given our experiments that used the same delivery vehicle for
DOX and TMZ but yielded different profiles, results suggest that
the chemical properties are likely the larger factor in determining
depth of drug distribution. We suspect that prolonged survival in
the systemic DOX is because of a low uniform level of DOX, which
may be more ideal in treating cancer cells beyond the site of release.
One important caveat to our findings is that the distribution
profiles were conducted in healthy rodents and not diseased
animals. The relatively hypoxic environment of cancer coupled
with the effect of tumor edema on diffusion may have a bearing
here. These studies were a proof of principle of chemotherapy
diffusion in brain tissue; they highlight the stark differences in
intracranial distribution for different agents. These differences
may explain limitations in efficacy of intracranial delivery, even
in circumstances where the chemotherapy is potent and induces
a robust apoptotic response (such as in intracranial DOX). Cer-
tainly, additional studies in diseased animals, where 3D models of
drug distribution may be compared with the spatial distribution of
biologic activity (such as cleaved caspase 3 expression), would
be enlightening.
The histological analysis of each experimental group was also
interesting. Intracranial delivery of chemotherapy led to more
robust expression of apoptotic markers for both TMZ and DOX.
However, the tissue evidence of cleaved caspase 3 did not ex-
plain or follow survival data; that is, intracranial (IC) DOX
animals actually displayed poor survival compared with systemic
DOX animals. The local activity of a drug may not adequately
increase survival, because the drug must also act at some dis-
tance away from the implantation site. The ability of micro-
capsular TMZ to induce apoptosis more robustly than any other
modality tested coupled with its wide distribution profile support
the improved survival observed in the intracranial TMZ group.
The CRL1666 cell line has been used in a model of breast
metastases to the spine. This body of work represents its first use
in a brain metastasis model. Metastases are noninfiltrative tumors,
and this cell line represents an appropriate histological model. In
sharp contrast, primary brain cancer models should ideally model
the infiltrative nature of these tumors. We believe that this body of
work represents the potential to use local intracranial drug de-
livery for a different indication: to treat brain metastases. Their
histologic nature may render them a better suited target by less-
ening the burden of broad drug distribution, because chemo-
therapies may only need to diffuse centimeters away from their
delivery site to be efficacious.
TMZ was chosen based on the experience of certain groups with
its use as a salvage treatment in breast metastases to the brain. In
vitro cytotoxicity experiments against this cell line supported the
choice to test its efficacy in vivo. Our results suggest that TMZmay
play a clinical role in treatment of breast metastases to the brain.
We feel that these results bear additional investigation. Currently,
it is only used in a rescue setting but may have a role in first-line
treatment of breast metastases to the brain, particularly when
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whole-brain radiation therapy may not be attractive given its long-
term effects on cognition. This body of work is not meant to sug-
gest that intracranial TMZ therapy alone may cure metastatic
breast cancer; however, these studies represent a proof of concept
that a chemotherapy-like TMZ, which until now, has been used
with limited success, may be more beneficial when delivered in-
tracranially in a device with tunable release kinetics.
Intracranial chemotherapy delivery has largely focused on
high-grade gliomas, which are infiltrative by nature and quite
different from metastatic lesions (13, 35). The limited efficacy of
current intracranial delivery schema, including Carmustine wafers,
may be attributed to the inability of chemotherapy to penetrate
brain tissue well. Our experiments support the notion that dif-
ferences in chemotherapeutic drug distribution seem to correlate
to tissue response to chemotherapy and length of survival. There-
fore, efforts in exploring intracranial drug delivery should focus, in
part, on strategies to improve and broaden the distribution of the
drug through tissue.
Conclusion
This work has shown that polymer microcapsules are capable of
achieving tunable rates of release of various chemotherapies.
TMZ microcapsules and systemic DOX seem to show promising
efficacy against breast metastases to the brain. We have also
shown that the tissues harvested from these experiments indicate
that TMZ microcapsules induce apoptosis at higher levels than
DOX microcapsules or systemic DOX. Finally, we have shown
that the drug distribution profiles for intracranial and systemic
DOX are quite different from that of intracranial TMZ and may
explain the differences observed in survival. Microcapsules offer
versatile targeted delivery without the requirement for intensive
drug formulation necessary for liposomal, nanoparticle, or sol-
vent drug-loading methods. These devices also have the unique
ability to simultaneously deliver multiple therapies and may be
used to deliver a variety of treatments beyond chemotherapy, in-
cluding nanoparticles and small molecules. The ability of a drug to
penetrate tissue requires additional investigation; drugs that show
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improved distribution profiles are likely to show more promise in
treating lesions of the brain. Finally, the limitations of prior efforts
at intracranial chemotherapy delivery may be overcome with focus
on new therapeutic targets and strategies to improve the ability of
a given chemotherapy to diffuse through CNS tissue. These insights
apply to non-CNS applications of local drug delivery, where drug
diffusion and inherent efficacy should be analyzed in target tissue.
In cases where tissue penetration is poor, drug formulation strat-
egies, although cumbersome, should improve the drug’s overall
effect. When this two-pronged strategy is used, many new appli-
cations of localized drug delivery may be identified and
further studied.
Materials and Methods
In Vitro Drug Release Kinetics of TMZ. Twelve milligrams TMZ was loaded into
LCP single- and multiple-hole devices. TMZ quantification was done using
HPLC with acetonitrile (92:8) mobile phase and UV absorption at 316 nm.
Interpolation of the readings with a standard curve was used to quantify the
amount of drug released.
In Vitro Drug Release Kinetics of DOX. DOX (3.5 and 5 mg) was loaded into LCP
single- and multiple-hole polymer microcapsules for in vitro drug release
characterization. DOX was quantified using the UV spectrophotometer at
481 nm. Interpolation of readings with a standard curve was used to quantify
the amount of drug released.
In Vitro Cytotoxicity. CRL1666 mammary adenocarcinoma cells were exposed
to TMZ and DOX at varying concentrations to determine cytotoxicity. Cell
proliferation was quantified using the MTT assay (Invitrogen).
In Vivo Experiments.
Tumor and device implantation. Briefly, animals were anesthetized, and the dura
was exposed. Stereotactic injection consisted of 75,000 tumor cells in 2.5 μL that
were placed into the brain at a depth of 3.5 mm and delivered over 2 min.
Devices were implanted at the time of tumor injection.
Efficacy of locally delivered TMZ and DOX. Two experiments were conducted to
determine the efficacy of locally delivered TMZ and DOX in tumor-bearing
rats. All TMZ microcapsules used in this experiment had a total TMZ payload
of 12 mg with a single 889-μm-diameter orifice cap. All DOX microcapsule
devices used in this experiment had a total payload of 5 mg with a single
180-μm-diameter orifice cap and one 430-μm-diameter orifice on the reser-
voir. The first experiment included five experimental groups and 40 F344
rats: (i) no treatment (n = 8), (ii) i.p. DOX (Doxil; Johnson & Johnson) on days
0, 6, and 13 after tumor implantation (n = 8), (iii) empty devices (n = 8), (iv)
TMZ-filled devices (n = 8), and (v) DOX-filled devices (n = 8). The second
study included 80 F344 rats divided into seven experimental groups: (i) no
treatment control (n = 16), (ii) oral TMZ by gavage on days 5–9 after tumor
implantation (n = 8), (iii) TMZ-filled LCP microcapsule (n = 8), (iv) DOX-filled
LCP microcapsule with 5 mg DOX payload (n = 8), (v) DOX-filled LCP
microcapsule with 3.5 mg DOX payload (n = 16), (vi) i.p. DOX on
days 0, 6, and 13 (n = 16), and (vii) empty device controls (n = 8). Overall,
animal survival was compared with that of untreated controls. Death was
the primary end point for efficacy studies. Kaplan–Meier survival curves
were constructed.
Immunohistochemical staining. Cleaved caspase 3 stainingwas developed by Cell
Signaling Technology. The whole brain was sectioned and counted in ag-
gregate, including tumor as well as peritumoral tissue.
Spatial drug distribution. Nondiseased F344 rats underwent implantation of LCP
devices with DOX or C13-radiolabeled TMZ. DOX LCP device animals were killed
on days 2, 4, 6, 8, and 10 (n = 4). Radiolabeled TMZ animals were killed on days
2, 4, 6, 8, and 10 (n = 5). Rodent brain tissue was homogenized and processed
for quantification of radiolabeled TMZ or DOX.
Western blotting. Anti-cleaved caspase 3 Western blotting was done on rat
brain tissue homogenates obtained from efficacy trials. Cleaved caspase 3
rabbit mAb was obtained from Cell Signaling Technology.
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